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1 INTRODUCTION 
 
Concerns regarding low vitamin D levels in patients with long-term underlying diseases have 
led to this thesis. In the northern latitudes, where Finland is situated, the sun shines adequately 
for vitamin D synthesis only a couple of months a year. The current guidelines for vitamin D 
supplementation have been questioned on logic, on science and on effective public health 
guidance. This thesis aims to clarify the factors affecting vitamin D deficiency and sufficiency 
in children with chronic illnesses.  
 
For this thesis we carried out a study involving fifty patients with the lowest and fifty patients 
with the highest vitamin D concentrations, who were selected from a cohort of 1351 
chronically ill children and adolescents who had had their vitamin D status assessed at 
Children's Hospital. The patient groups with low and high vitamin D levels were assessed for 
clinical differences. The factors analyzed included the underlying disease, body size, age, 
ethnic background, use of vitamin D supplements and the season when the blood sample was 
taken. 
 
The literature on vitamin D was carefully reviewed. The functions and metabolism of vitamin 
D in general are presented. Vitamin D deficiency and toxicity are described and the factors 
that affect vitamin D concentration in plasma are discussed. Finally the current guidelines in 
Finland  and  in  the  United  States  are  introduced.  The  third  chapter  concerns  the  aims  of  the  
thesis more specifically and is followed by an introduction to the study subjects and methods 
that have been used in the thesis. The fifth chapter presents the results of the thesis. The 
significance of the findings is further discussed in Discussion and the study findings are 
correlated with the current state of vitamin D policy. The major conclusion for the thesis is 
that  new  recommendations  for  children  with  long-term  underlying  diseases  are  required  for  
sufficient concentrations of vitamin D throughout the year.  
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2 REVIEW OF THE LITERATURE  
 
2.1 Vitamin D metabolism and functions 
 
2.1.1 Sources of vitamin D 
 
Vitamin D is a prohormone (7-dehydrocholesterol) that is synthesized in the skin. It is present 
in the lipid bilayer of plasma membrane in epidermal keratinocytes and dermal fibroblasts. It 
is most abundant in the stratum spinosum and stratum basale. Exposure to UVB radiation 
initiates vitamin D synthesis. It causes double bonds to rearrange and 7-hydrocholesterol is 
converted to previtamin D3, as shown in Figure 1. 
 
Previtamin D3 then isomerizes to vitamin D and is transferred to dermal capillaries. Vitamin 
D binds with vitamin D-binding protein (DBP) in the circulation, this drives the conversion 
equilibrium of previtamin D3 to  vitamin  D  towards  formation  of  vitamin  D.  Vitamin  D  can  
also be acquired from nutrition. The main sources are fish rich in fat, egg yolk and 
mushrooms that have grown in sunny places (Table 1). Plant-derived vitamin D is in the form 
of D2 and animal-derived is in D3. Vitamin D from nutrition is absorbed from the gut and is 
packed into chylomicrons. Chylomicrons circulate first in the lymphatic circulation and then 
enter venous blood, where vitamin D slowly diffuses to DBP. Chylomicrons are processed by 
lipoprotein lipase (LPL) in the peripheral tissues such as adipose and muscle tissue. However 
the liver takes most of the vitamin D when it processes the chylomicron remnant. 
 
Product  Vitamin D content (?g / 100 mg)  
Eel  25.6  
River lamprey  25.6  
Pike perch  24.6  
Whitefish, pollan, lavaret 22.0  
Baltic herring  18.0  
Chantarelle  12.8  
Margarine  9.2  
Salmon  8.9  
Tuna  7.2  
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Egg Yolk  6.5  
Lorchel 5.7  
Mushroom milk caps 5.3  
Boletus edible 2.9  
Egg, boiled  2.2  
Coalfish 1.5  
Milk  1.0  
Liver  0.8  
Meat  0.2-0.5  
Champignon  0.2  
Table 1. Vitamin D contents in different dietary sources. Modified from (1) 
 
 
Figure 1. Vitamin D is obtained either from food or synthesized in the skin. Its further processing occurs in the 
liver and then in the kidney. The active form (1,25(OH)2D) is under tight regulation by its own negative feedback 
mechanism, parathyroid hormone (PTH), plasma concentration of phosphorus, growth hormone (GH) and 
estrogen. (2)  
 
4 
 
 
2.1.2 Metabolism of vitamin D 
 
Vitamin D, whether obtained from nutrition or synthesized in the skin, is processed further in 
the  same way in  the  liver  and  then  in  the  kidney.  First,  vitamin  D is  25-hydroxylated  in  the  
liver by CYP enzymes and this 25(OH)D is then quickly released to the plasma where it 
constitutes the main vitamin D pool of the body. Second, 25(OH)D is carried by DBP to the 
kidney where it is further hydroxylated through 1-?-hydroxylation to 1,25(OH)2D by 
CYP27B1. This 1,25(OH)2D  i.e.  calcitriol  is  the  active  form  of  vitamin  D.  The  vitamin  D  
half-life in plasma is ?4-6 h but in the whole body it is ? 2 months (3). 
 
All forms of vitamin D bind to DBP but the affinity differs. There are two forms of 25(OH)D, 
25(OH)D2 and 25(OH)D3 depending  whether  it  is  derived  from  (D2) ergocalciferol or (D3) 
cholecalciferol. 25(OH)D2 has  stronger  affinity  to  DBP  than  25(OH)D3 (15  d)  and  has  thus  
longer half-life. 25(OH)D3 is considered to be more efficient than 25(OH)D2 due to its ability 
to up-regulate vitamin D receptor (VDR) and because much more of vitamin D2 is 
metabolized to 24(OH)D2 than vitamin D3 to 24(OH)D3 (4). Normally in physiologic state 
only 2-5% of 25(OH)D is bound to DBP. Other metabolites including inactive forms have 
equal or stronger affinity to DBP than 25(OH)D, and the active form 1,25(OH)2D has the 
lowest affinity. The affinity to DBP determines the half-life of the metabolites: the stronger 
the  affinity,  the  longer  the  half-life.  The  significance  of  this  is  that  the  inactive  metabolites,  
bound to the DBP, are kept in the plasma pool away from the VDR and nuclear transcriptional 
machinery while the active form is available for VDR to which its affinity is greatest. Thus 
the active form has the shortest half life (10-20 h). Under physiologic conditions 1,25(OH)2D 
is the only active metabolite that binds to VDR. It seems that other metabolites bind to VDR 
only in vitamin D toxicity. (5) 
 
While sunlight sets the vitamin D synthesis in motion it also controls that concentrations do 
not rise too high. Sunlight inactivates previtamin-D3 to inactive lumisterol3 or tachysterol3. It 
can also inactivate vitamin D3 to suprasterol I, suprasterol II or 5,6,-transvitamin. This is 
probably the explanation why there are no reports on vitamin D intoxication due to excessive 
exposure to sunlight. (6) 
 
5 
 
It has been shown that 1-?-hydroxylation can also occur in other sites than the kidney, such as 
alveolar macrophages, lymph nodes, placenta, colon, breasts, osteoblasts, activated 
macrophages and keratinocytes. This illustrates a paracrine role for 1,25(OH)2D. In 
macrophages stimulation of VDR induces toll-like receptor pathway. This results in up-
regulation of mRNA production of cathelicidin, which is antimicrobial protein that kills 
Myobacterium tuberculosis (7). Also other mechanisms for antimicrobial effects have been 
demonstrated. (8)  
 
2.1.3 Functions of vitamin D 
 
One of the main functions of Vitamin D is to maintain proper calcium and phosphorous 
levels. Figure 2 illustrates the plasma calcium homeostasis and the effect of 1,25(OH)2D and 
PTH.  The active vitamin D (1,25(OH)2D) increases calcium absorption in the gut and bone 
resorption in the skeleton, thereby increasing the plasma calcium pool. However, the overall 
effect of vitamin D in the skeleton is to increase mineralization: by increasing renal distal 
tubular  reabsorption  of  phosphorous,  it  raises  the  plasma  ratio  of  calcium  and  phosphate  
which induces bone mineralization. 
 
In  the  intestinal  epithelium  activation  of  VDR  increases  transcription  of  proteins  that  
participate in calcium absorption. Activation of this receptor results in genomic effects that 
increase synthesis of epithelial calcium channels and binding proteins (e.g. Calbindin) in the 
epithelial cells. Calbindin is a protein with high affinity for calcium in the cytoplasm of 
intestinal epithelial cells. It reduces the amount of free ionized calcium and thus hastens 
absorption of calcium by lowering the potential difference of calcium between gut lumen and 
epithelial cell cytoplasm. Vitamin D thus stimulates the active transcellular part of calcium 
absorption but has no effect on the passive paracellular pathway. (9) Only 10-15% of dietary 
calcium is absorbed without vitamin D (10). Vitamin D also has a negative-feedback 
mechanism on secretion of parathyroid hormone (PTH) which in turn further decreases bone 
demineralization. (11,12) 
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Figure 2. Plasma calcium homeostasis. Plasma calcium pool is obtained from nutrition by intestine, from 
primary urine by kidney and by demineralization of bone. Parathyroid hormone (PTH) and the active form of 
vitamin D (1,25(OH)2D) controls this system. Plasma calcium pool is essential for normal function of 
neuromuscular transmission and mineralization of bone. 
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In addition to a significant role in calcium homeostasis, vitamin D has been shown to function 
in several other organ systems. Tables 2 and 3 condense these suggested effects. 
 
Category Disease Hypothetical mechanism 
Glucose metabolism ? Type 2 Diabetes 
Mellitus 
? Active form of vitamin 
D directly stimulates insulin 
receptor 
Autoimmune disease ? Multiple sclerosis 
(MS) 
? Rheumatoid arthritis 
? Crohn's Disease 
? Type 1 diabetes 
? Decrease in formation 
of macrophages from 
monocytes and thus reduction 
in antigen representing to T 
lymphocytes    
? Decrease in synthesis 
of immunoglobulins by B 
lymphocytes 
? Maturation of dendritic 
cells is suppressed   
 
Table 2. Multiple effects of vitamin D (13-15)  
 
Category Disease Hypothetical 
mechanism 
Cancer ? Colon, breast and 
prostate cancer 
? Antiproliferative 
effect on cells 
? promotes 
ordered differentiation 
? prevents 
spreading of tumors by 
inhibiting apoptosis, 
telomerase activity and 
angiogenesis 
Cardiovascular disease ? Hypertension 
? Left ventricular 
hypertrophy  
? Congestive heart 
failure  
? Deficiency is 
associated with 
malfunction of calcium 
channels and activation 
on renin-angiotensin 
system 
? Deficiency is 
associated with 
formation of foam cells 
and increased uptake of 
low-density lipoproteins 
in macrophages  
Glucose metabolism ? Type 2 Diabetes 
Mellitus 
? Correction in 
vitamin D level 
improves glucose-
stimulated insulin 
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release 
? Uptake of 
glucose is improved by 
myocytes and 
adipocytes when low 
vitamin D level is 
corrected 
? Lowers insulin 
resistance by 
suppressing renin-
angiotensin-aldosterone 
system 
? Improvement in 
insulin resistance in 
peripheral tissues by 
activation of PPAR delta 
receptor 
 
 
Table 3. Multiple effects of vitamin D deficiency (13-15) 
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2.2 Vitamin D deficiency and intoxication 
 
2.2.1 Definitions of Vitamin D deficiency 
 
Vitamin D deficiency is associated with rickets in children and osteomalacia in adults. 
Biochemical manifestations of vitamin D deficiency comprise raised levels of alkaline 
phosphatase (ALP) and parathyroid hormone (PTH). Plasma concentrations of calcium and 
phosphate decrease, but in early phase of deficiency they may be normal.(2)(16) Table 4 
illustrates the definitions for normal and abnormal vitamin D concentrations.   
  
Definition Concentration in plasma 
Severe Vitamin D deficiency ? 12,5 nmol/L 
Vitamin D insufficiency ? 37,5 nmol/L 
Vitamin D sufficiency 50-250 nmol/L (80 nmol/L) 
Excess > 250 nmol/L 
Intoxication > 375 nmol/L 
  
Table 4. Definitions for vitamin D concentrations (16) 
 
2.2.2 Mechanisms for vitamin D deficiency 
 
Vitamin D deficiency can be due to defects in formation, supply, absorption or metabolism. 
Most commonly deficiency results from lack of sunlight exposure due to sunscreen, clothes or 
geographic location. Deficiency related to supply is mainly a problem at latitudes where 
sunlight is sufficient only few months a year (latitudes above 37°N (17)) and is due to lack of 
eating oily fish. Problems with absorption are mainly due to bowel disorders e.g. fat 
malabsorption, and problems with metabolism are due to renal disease e.g. inherited or 
acquired kidney disease.   
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2.2.3 Effects of vitamin D deficiency 
 
Vitamin D deficiency impairs absorption of dietary calcium and phosphorus which results in 
increased PTH secretion. Only 10 to 15% of dietary calcium and 60% of phosphorus is 
absorbed without vitamin D (18). Raised PTH levels in secondary hyperparathyroidism 
increase bone resorption (and thereby decrease bone mineral density) in order to increase 
plasma calcium levels. In addition, PTH has an effect on renal tubular function. It increases 
calcium reabsorption and phosphate secretion in renal tubules. This prevents precipitation of 
calcium and phosphate in tissues, which would otherwise be inevitable when bone is 
demineralized. In the early phase of vitamin D deficiency calcium and phosphorous levels can 
be within normal range due to compensatory mechanisms. 
 
Secondary hyperparathyroidism results in inadequate calcium-phosphate supply for bone 
mineralization. This leads to a decrease in bone mineral density and causes osteopenia and 
osteoporosis.  In  growing  children  this  leads  to  bone  deformities.  In  adults  epiphyseal  plates  
are closed and skeletal bones have sufficient calcium and phosphorus reserves which prevent 
bone deformities, but still BMD is reduced and osteomalacia occurs. This manifests as an 
increased risk for fractures and isolated or generalized pains in bone and muscle tissue. 
Vitamin D deficiency causes also muscle weakness especially in the elderly and in children. 
Affected children have difficulties in standing and walking whereas the elderly have impaired 
balance and increased risk for falling and fracture. (16) 
 
 
2.2.4 Vitamin D intoxication 
 
Vitamin D intoxication causes hypercalciuria, hypercalcemia, and soft-tissue calcification. 
The clinical manifestations of intoxication include kidney disorders, renal insufficiency, 
gastrointestinal symptoms and constipation, and arterial hypertension. 
 
Three theories about the mechanisms of vitamin D intoxication have been presented: 
1. Vitamin D intake raises plasma 1?25(OH)2D concentrations, which increases cellular 
??25(OH)2D concentrations. 
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2. Vitamin D intake raises plasma 25(OH)D to µmol/L concentrations that exceed the DBP 
binding capacity and then “free 25(OH)D” enters the cell, where it has direct effects on gene 
expression. 
 
3. Vitamin D intake increases the concentration of many vitamin D metabolites, especially 
vitamin D itself and 25(OH)D. These concentrations exceed the DBP binding capacity and 
cause release of free 1?25(OH)2D, which affects target cells.  
 
The actual mechanism for intoxication is more likely to be a combination of all the three 
mechanisms rather than one of them alone. (5)    
 
All known poisonings in adults with vitamin D reflect misuse on an industrial scale (19). 
Based on literature review, all reports of vitamin D toxicity showing convincing 
evidence of hypercalcemia involve serum 25(OH)D concentrations well above 200 
nmol/L, which requires a daily intake of ? 1000 µg (40 000 IU) (20). These findings 
are summarized in Figure 3. 
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Figure 3. Dose response of vitamin D to circulating 25(OH)D concentrations. “X” represents intoxication and 
the arrow marks the lowest dose that has caused hypercalcemia, it is an outlier because the patient was given a 
single dose of 7500 µg instead of 250 µg/d. (20) 
 
There are few patient subgroups who can develop vitamin D intoxication because of increased 
endogenous formation of 1,25(OH)2D. Patients with chronic granuloma-forming disorders 
(e.g. sarcoidosis), some lymphomas and primary hyperparathyroidism have increased 
metabolism of 25(OH)D to 1,25(OH)2D.  Patients  with  these  conditions  are  at  risk  of  
developing vitamin D intoxication and yet have low plasma concentrations of 25(OH)D. 
Because of the chronic inflammation in sarcoidosis there is a notable increase in macrophages 
at the inflammation site. Macrophages have the CYP27B1 enzyme that converts 25(OH)D to 
1,25(OH)2D. This results in hypercalciuria and vitamin D deficiency at the same time because 
1,25(OH)2D levels are elevated and 25(OH)D levels diminished (21). Also subcutaneous fat 
necrosis may cause hypercalciuria, which is probably caused by 1?-hydroxylase activity 
within the inflammatory infiltrate (22). 
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2.3 Factors affecting plasma concentration of Vitamin D 
 
2.3.1 Primary factors 
 
Factor Mechanism 
Age  Increment in adipose tissue and efficiency of 
vitamin D photosynthesis decreases with 
increasing age (17) 
Sex Men have 10-15% less fat with same BMI 
  
BMI Increment in fat tissue increases volume of 
sequestration. Release of vitamin D from 
adipose tissue is extremely slow and 
proportional to the concentration. Stronger 
correlation with serum adiposity. (23,24) 
UV-exposure Affects on synthesis of previtamin-D in the base 
membrane of the skin 
Pigment Affects directly the amount of UV- radiation that 
reach the base membrane of the skin  
Physical activity Affects lean body mass, time spent outdoors 
Nutrition Dietary intake of vitamin D 
Season and 
geographic 
location 
Affects the amount of UV-radiation  
  
 Table 5. Factors affecting vitamin D concentration 
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2.3.2 Medication and illnesses 
 
Medication and illnesses may have a great influence on vitamin D levels. Mechanisms for 
drugs to cause hypovitaminosis are mainly due to induction of enzymes that catabolize 
vitamin D. Diseases that cause hypovitaminosis are usually associated with problems in 
absorption or increased secretion of vitamin D. 
      
Medication for epilepsy e.g. Carbamazepine therapy decreases levels of vitamin D (25). 
Carbamazepine induces CYP 450 enzymes that catalyze formation of inactive metabolites of 
vitamin D in liver and thus reduces levels of vitamin D. Also anticonvulsants, and drugs to 
treat HIV/AIDS increase catabolism of 25(OH)D and 1,25(OH)2D. (2,16) 
 
Disorders affecting vitamin D concentration, categorized by mechanism, include: 
 
1. Intake problems 
Eating disorders e.g. anorexia. CP or other neurological problems, food allergies, severe skin 
diseases in which skins synthesis is impaired can cause insufficient intake of vitamin D.  
 
2. Absorption problems 
Patients with malabsorption syndromes and bariatric patients have often vitamin D deficiency 
because  of  malabsorption  of  the  fat-soluble  vitamin.  Hypo  function  of  pancreas,  chronic  
bowel disease, and celiac disease are causes for vitamin D insufficiency due to malabsorption.   
 
3. Metabolism problems 
Severe liver disease which prevents 25-hydroxylation in liver and renal diseases where 1-
hydoxylation is impaired are causes for hypovitaminosis due to inadequate formation of 
1,25(OH)2D. 
Nephrotic syndrome may cause losing of 25(OH)D bound to DBP in urine and thus cause 
hypovitaminosis.     
Inherited vitamin D dependent rickets 1A (VDDR1A) is an autosomal recessive disorder that 
manifests itself as rickets. It is caused by a mutation in genes that code the 1-alpha-
hydroxylase in the kidney. Thus the active form of vitamin D is not formed.  
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4. Vitamin D resistance   
The defective function of VDR that causes total defect in vitamin D actions even though 
vitamin D is present. This can be compensated with high doses of 1,25(OH)2D. 
 
2.4 Dietary guidelines  
 
2.4.1 Current guidelines in Finland 
 
 
Group RDA UL Notions 
Children 
under age of 
21 
10µg 
(400 IU) 
25 µg 
(1000IU) 
Starting at 2 weeks after birth all 
year round whether or not child has 
other vitamin D source 
Age 2-181 7,5µg  
(300 IU) 
Before age 10 
yrs 25µg 
(1000 IU) 
After age 10 
yrs 50µg  
(2000 IU) 
Regular and remarkable usage of 
richly fortified product e.g. milk can 
cause excess intake of vitamin D 
Pregnant and 
lactating 
women1 
10µg  
(400 IU) 
50µg  
(2000 IU) 
All year round 
Age 18-60 7,5µg  
(300 IU)  
50µg  
(2000 IU) 
Vitamin D supplements should be 
used from October to end of March 
if dietary intake of vitamin D is not 
regular  
Over age of 
602 
20µg  
(800 IU) 
50µg  
(2000 IU) 
All year round, lower dose can be 
suggested if dietary intake is highly 
abundant 
Table 6. 
Sources: 
1 Terveyden ja hyvinvoinnin laitos, Valtion ravitsemusneuvottelukunta ja Suomen Lastenlääkäriyhdistys, 2011  
 
2 Ikääntyneiden ravitsemussuositukset, 2010  
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2.4.2 Current recommendations in the United States   
 
Current guidelines for vitamin D intake in the United States are shown in table 7. Those are 
meant for general population and in addition The Endocrine Society has published their own 
recommendations for people who are at risk to develop vitamin D deficiency. 
 
Endocrine Society guidelines: 
 
? Agree with the recommendations of Institute of Medicine for general population 
? Have different guidelines for patients at risk for vitamin D deficiency 
? Screening of 25(OH)D concentration is recommended for patients who are at risk for 
vitamin D deficiency. 
? Do not recommend screening of 1,25(OH)2D; it is necessary only in certain 
conditions, such as in inherited disorders of vitamin D and phosphate metabolism. 
 
  
 
AI = Adequate intake 
EAR = Estimated average requirement 
RDA = Recommended daily allowance 
UL = tolerable upper intake limit 
NOAEL = No observed adverse effect level 
LOAEL = Lowest observed adverse effect level 
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Table 7. Vitamin D intakes recommended by the IOM and the Endocrine Practice Guidelines Committee (18)
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3 AIMS OF THE THESIS 
 
Some recent studies have shown that vitamin D deficiency is prevalent in Finnish children. 
More than 50% of Finnish school children were found to be vitamin D deficient. (26,27)  
Children with chronic illness may have even greater risk for vitamin D deficiency. The risk 
factors may be related to the underlying chronic illness or its treatment. This study was 
carried out to further define factors that predispose to or protect from vitamin D deficiency in 
children with a chronic illness.  
 
The specific aims were to: 
 
? Define the clinical background of children with high and low levels of vitamin D among 
pediatric patients visiting the tertiary pediatric out-patient clinics in Children’s Hospital, 
Helsinki University Central Hospital, and assess the impact of the underlying disease on 
vitamin D status 
? Evaluate the effect of patients’ age, body size, and ethnic background on vitamin D 
concentration 
? Determine the significance of seasonal variation for vitamin D status in these children. 
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4 SUBJECTS AND METHODS  
 
The study cohort included 100 subjects who were chosen from a register-based cross-
sectional study on 1351 children, who visited the pediatric outpatient clinics at Children´s 
Hospital, Helsinki University Central Hospital, during 2007-2010. Vitamin D samples had 
been obtained as part of routine clinical assessment, at the same time with other clinical 
laboratory tests. The age range of patients was 0-18 years. Subjects included in this study had 
one or several chronic diseases for which they required follow-up at a tertiary center; hospital 
inpatients were not included. Results of their S-25-OHD measurements were collected from 
the database of the Hospital´s Central Laboratory (HUSLAB, Hospital District of Helsinki 
and Uusimaa), where all the samples had been analyzed. 
 
S-25-OHD measurements were taken based on the judgment of individual clinician, as 
clinically indicated. Several patients had repeated measurements during the follow-up period 
but only the first measurement obtained during the study period 2007-2010 was included in 
the analyses. The selection of the 100 subjects for the present study was made on the basis of 
vitamin D level. Subjects with highest and lowest vitamin D levels were selected, 50 patients 
for each group. Patient records of these patients were examined and information was collected 
for the following variables: height, weight, season for the time of sampling, diagnosis of the 
underlying disease, medication, use of vitamin D supplements, ethnic background. The study 
protocol was approved by the Research Ethics Committee of Hospital District of Helsinki and 
Uusimaa. 
 
Statistical analyses were performed with SPSS version 19.0 for Windows. Chi Square test was 
used to assess the significance between nominal variables in the two groups. Independent T 
test was used to assess the statistical significance of differences between various continuous 
variables in the two groups. All the graphs were done with the same SPSS program. Results 
were considered statistically significant when p<0.05. 
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5 RESULTS 
 
The study cohort included 50 children with low and 50 children with high S-25-OHD 
concentration. The mean concentration in the high vitamin D group was 119.3 nmol/L and in 
the low vitamin D group 15.3 nmol/L. There were no patients with levels suggesting 
intoxication and the maximum S-25-OHD level was 168 nmol/L. Some patients had such a 
low vitamin D level that it was below detection limit. For the data analysis such results were 
registered as 5 nmol/L. There were no statistically significant differences in distribution 
between sexes in the two groups (p>0.69). 
 
Age distribution in the two groups differed drastically. In the high value group younger 
patients were overrepresented, especially the group of 0-2 year-old patients. In contrast, older 
patients were overrepresented in the low value group, particularly 12-18 year-old patients, as 
shown in Figure 4. The mean age in the low value group was 5.9 years and in the high value 
group 13.7 years with standard deviations of 5.5 and 3.5 years, respectively. 
 
 
Figure 4. Age distribution in low and high value groups. 
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There were no differences in the height Z-score or degree of over-weight between the subjects 
with low and high vitamin D concentrations. The effect of season is shown in Figure 5. The 
high level samples were taken more often in the summer and autumn and the count 
progressively decreased toward spring, while low values were taken more often in winter and 
spring than summer and autumn (p<0.05 for the difference between the groups).  
 
 
Figure 5. Number of vitamin D samples obtained in different seasons. 
 
The use of vitamin D supplements was significantly more common among those with high 
than low values (p<0.05). Within the group of high values 88% used vitamin D supplements 
whereas only 23 % in the low vitamin D group used vitamin D supplements. Use of 
supplements in the different age groups is shown in Table 8. 
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Table 8. Use of vitamin D supplements in different age groups. 
 
Ethnicity seemed to be a risk factor for low vitamin D levels.  In this material  20 out of 100 
children had non-Finnish background. Only 2 of them were in the group of high vitamin D 
values and 18 were in the group of low vitamin D values. (p <0.05) (Figure 6). 
 
 
Figure 6. Patients with non-Finnish ethnic background in the low and high vitamin D groups.   
 
 
Age group 
1-2 
years 
2-8 
years 
8-12 
years 
12-18 
years 
Use of vitamin D 
supplement 
Do not use 
vitamin D 
supplement 
Count 2 4 8 29 
% within Age 
group 
11% 22% 62% 63% 
Uses vitamin D 
supplement 
Count 17 14 5 17 
% within Age 
group 
89% 78% 38% 37% 
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There was no correlation between a specific underlying condition and the group of high or 
low vitamin D levels (p= 0.106). Patients with a nephrologic disease were more prevalent in 
the high value group. However, almost all of those (6 out of 7) with increased creatinine 
levels were in the group of high vitamin D levels. High creatinine levels suggest that high S-
25-OHD values may partly reflect impaired renal vitamin D hydroxylation and in such case 
suggest poor rather than good vitamin D status despite high S-25-OHD. 
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6 DISCUSSION 
 
Vitamin  D deficiency  is  prevalent  among Finnish  children.  Several  studies  have  shown that  
also children with chronic illness often have low vitamin D levels. This study was carried out 
to  identify  the  factors  that  predispose  or  protect  from  vitamin  D  deficiency.  The  results  
suggest that the main predisposing factors for vitamin D deficiency in children with chronic 
illness are older age, lacking use of vitamin D supplements and non-Finnish ethnic 
background.   
 
The results can be largely explained with the former vitamin D recommendations. The former 
recommendations commended vitamin D supplementation only up to 2 years of age and older 
children and adolescents have fallen through the net. The patients in our cohort have been 
treated according to the old recommendations. The use of supplements was clearly more 
common in young age groups, especially in the group of 0-2 year-old patients (90%) than in 
the group of 12-18 year-old patients (37%). Within the group of high vitamin D values 88% 
used supplements whereas in the group of low values the corresponding proportion was 23%. 
The recommendations for vitamin D supplementation have recently been changed and the 
new recommendations cover all age-groups up to 18 years of age, but the dosage for 0-2 year-
olds is higher than for 2-18 year-olds, as shown in Table 6. This study does not show the 
effect  of  the  new  recommendations,  but  it  has  been  already  questioned  whether  the  new  
recommendations are sufficient to satisfy the demands (27,28). 
 
IOM recommendations have also been criticized for being too cautious and illogical (29), 
even though the recommendations are higher than the new Finnish ones. The Finnish 
nutritional advisory board states in their report that the recommended dose cannot further be 
elevated or “it would be even harder or even impossible to fulfill it without usage of food 
supplements in the whole population”. By saying “then it is not primarily a question of a 
recommendation of a nutrient” they indicate that, if necessary, the decision should be done by 
some other instance. 
 
The influence of seasons and the importance of using supplements can be explained by the 
geographic location. Helsinki is located at the latitude 60°N (comparable to South Alaska). As 
Holick  states  (17),  sunlight  is  sufficient  only  for  a  few months  a  year  at  the  latitudes  above  
37°N (e.g. Southern Italy and Spain). Thus only in the summer one can acquire sufficient 
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amounts of vitamin D synthesized by irradiation from the sun, but vitamin D stores last only a 
few months. Inevitably vitamin D concentration lowers in winter and spring without vitamin 
D supplementation, which is consistent with the results of this thesis. 
 
More people with a non-Finnish background were found in the low level group. People with a 
non-Finnish background usually have darker pigment and therefore more melanin which 
functions as the body’s natural sun block (6). It seems that vitamin D supplementation is vital 
for these people in the Northern latitudes. This has already been demonstrated in other studies 
(30). 
 
Various diagnoses were evenly distributed in the high and low vitamin D level groups. 
Vitamin  D deficiency  was  a  problem regardless  of  the  disease.  However,  the  data  showed a  
trend (p=0.106) that patients with a nephrotic disease were abundant in the group of high 
values. Six out of 13 of these patients had a high creatinine level which may indicate 
decreased 1-?-hydroxylation in the kidney and accumulation of the measured form 
(25(OH)D) of vitamin D. Thus it is important to follow the concentration of 1,25(OH)2D in 
these patients.  Another study (31) reveals that also organ transplant recipients and patients 
with juvenile rheumatological conditions are at risk to develop vitamin D insufficiency. The 
study indicated that only 3% and 25% of these patients, respectively, had the targeted vitamin 
D level (?80nmol/L).  
 
Insufficient vitamin D levels seem to be the common trend in the whole study cohort of 1351 
patients (Holmlund-Suila et al., manuscript). Supplementation, being a significant indicator 
for vitamin D deficiency, should be given more thought when treating children with long-term 
underlying diseases. This subgroup of patients has many risk factors for developing 
osteoporosis. Since the most significant prognostic factor for osteoporosis is the peak value of 
bone density that is achieved in early life, it is important to pay attention to the treatment of 
the skeletal system. Vitamin D being one of the main environmental factors affecting bone 
mass, and being easy to administer, it is justified to screen for vitamin D concentration in 
these patients. 
 
The results of the present study indicate that special recommendations are needed for those 
who are at risk to develop vitamin D deficiency. It would also be in line with the report of the 
Finnish Nutrition Advisory Board that states: “certain special groups can be advised and 
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special recommendations can be made e.g. for little children and the elderly”. This has been 
done in the United States by the Endocrine Society of Clinical Practice as can be viewed in 
the right side of Table 7. They have also made a list of indications for screening vitamin D 
levels, shown in Table 9. Patients with long-term underlying diseases need more vitamin D 
than healthy children. While low levels of vitamin D are measured also in the summer the 
recommendations should be round-the-year.  
 
 
  
Table 9. Candidates for screening vitamin D concentration. (18) 
 
 
This thesis was a retrospective cross-sectional analysis and has thus limitations in many 
aspects. Because the sample was not randomly selected we were not able to evaluate 
correlation between various variables. The strength of this thesis lies in the comparison of the 
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two chosen groups and in pointing out their clinical differences for further investigation. The 
thesis shows common factors in patients who have low or high vitamin D levels.  
 
To make the thesis more reliable we could have taken bigger groups under comparison. That 
could have made it possible to find out predisposing underlying diseases for vitamin D 
deficiency. The information for the thesis was collected from the patient records and 
incomplete patient records created the greatest source of error. Because the thesis was made in 
retrospective manner it precludes the possibility to effect on collection of information.  
 
In conclusion, use of vitamin D supplements is fundamental in achieving sufficient vitamin D 
concentrations in plasma throughout the year in children with chronic illnesses. The former 
recommendations failed to attain this state. New recommendations should include special 
recommendations for this subgroup of patients. The observed severe vitamin D deficiency in 
several patients is a clear indication for screening 25(OH)D during follow-up in children with 
chronic illnesses.  
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